Single Agent Dose-Escalation

Day 1:

1. Wong, C.H., Siah, K.W. and Lo, A.W., 2019. Estimation of clinical trial success rates and related parameters. *Biostatistics*, *20*(2), pp.273-286.
2. Cross, J., Lee, H., Westelinck, A., Nelson, J., Grudzinskas, C. and Peck, C., 2002. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980–1999. *Pharmacoepidemiology and drug safety*, *11*(6), pp.439-446.
3. Storer, B.E., 1989. Design and analysis of phase I clinical trials. *Biometrics*, pp.925-937.
4. Hansen, A.R., Graham, D.M., Pond, G.R. and Siu, L.L., 2014. Phase 1 trial design: is 3+ 3 the best?. *Cancer control*, *21*(3), pp.200-208.
5. Lin, Y. and Shih, W.J., 2001. Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. *Biostatistics*, *2*(2), pp.203-215.
6. Conaway, M.R. and Petroni, G.R., 2019. The Impact of Early-Phase Trial Design in the Drug Development ProcessThe Role of Early-Phase Design. *Clinical Cancer Research*, *25*(2), pp.819-827.
7. Wheeler, G.M., Mander, A.P., Bedding, A., Brock, K., Cornelius, V., Grieve, A.P., Jaki, T., Love, S.B., Odondi, L.O., Weir, C.J. and Yap, C., 2019. How to design a dose-finding study using the continual reassessment method. *BMC medical research methodology*, *19*(1), pp.1-15.
8. O'Quigley, J., Pepe, M. and Fisher, L., 1990. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. *Biometrics*, pp.33-48.
9. O'Quigley, J. and Shen, L.Z., 1996. Continual reassessment method: a likelihood approach. *Biometrics*, pp.673-684.
10. Whitehead, J. and Williamson, D., 1998. Bayesian decision procedures based on logistic regression models for dose-finding studies. *Journal of Biopharmaceutical Statistics*, *8*(3), pp.445-467.
11. Babb, J., Rogatko, A. and Zacks, S., 1998. Cancer phase I clinical trials: efficient dose escalation with overdose control. *Statistics in medicine*, *17*(10), pp.1103-1120.
12. Neuenschwander, B., Branson, M. and Gsponer, T., 2008. Critical aspects of the Bayesian approach to phase I cancer trials. *Statistics in medicine*, *27*(13), pp.2420-2439.
13. Tighiouart, M. and Rogatko, A., 2010. Dose finding with escalation with overdose control (EWOC) in cancer clinical trials. *Statistical Science*, *25*(2), pp.217-226.
14. Wheeler, G.M., Sweeting, M.J. and Mander, A.P., 2017. Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials. *Statistics in medicine*, *36*(16), pp.2499-2513.
15. Mozgunov, P. and Jaki, T., 2020. Improving safety of the continual reassessment method via a modified allocation rule. *Statistics in medicine*, *39*(7), pp.906-922.
16. Wheeler, G.M., Sweeting, M.J. and Mander, A.P., 2016. AplusB: a web application for investigating a+ B designs for phase I Cancer clinical trials. *PloS one*, *11*(7), p.e0159026.
17. Wages, N.A. and Petroni, G.R., 2018. A web tool for designing and conducting phase I trials using the continual reassessment method. *BMC cancer*, *18*(1), pp.1-8.
18. Pallmann, P., Wan, F., Mander, A.P., Wheeler, G.M., Yap, C., Clive, S., Hampson, L.V. and Jaki, T., 2020. Designing and evaluating dose-escalation studies made easy: the MoDEsT web app. *Clinical Trials*, *17*(2), pp.147-156.
19. Ji, Y., Liu, P., Li, Y. and Nebiyou Bekele, B., 2010. A modified toxicity probability interval method for dose-finding trials. *Clinical trials*, *7*(6), pp.653-663.
20. Liu, S. and Yuan, Y., 2015. Bayesian optimal interval designs for phase I clinical trials. *Journal of the Royal Statistical Society: Series C (Applied Statistics)*, *64*(3), pp.507-523.
21. Yan, F., Mandrekar, S.J. and Yuan, Y., 2017. Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical TrialsKeyboard: A Bayesian Design for Phase I Clinical Trials. *Clinical Cancer Research*, *23*(15), pp.3994-4003.
22. Wages, N.A., Iasonos, A., O'Quigley, J. and Conaway, M.R., 2020. Coherence principles in interval-based dose finding. *Pharmaceutical statistics*, *19*(2), pp.137-144.
23. Bové, D.S., Yeung, W.Y., Palermo, G. and Jaki, T., 2019. Model-based dose escalation designs in r with crmpack. *Journal of Statistical Software*, *89*, pp.1-22.